Target intelligence / Profile preview

Protective antigen protein (Bacillus anthracis) (PA)

Target
PA
Molecular classification
Bacterial toxin component, Pore-forming protein, Other
01

Overview

Protective antigen is a protein secreted by *Bacillus anthracis* and is the cell-binding component of the anthrax toxin complex. It binds to anthrax toxin receptors on mammalian cells (such as ANTXR1 and ANTXR2), is proteolytically activated on the cell surface, oligomerizes to form a heptameric or octameric pre-pore, and facilitates the translocation of lethal factor and edema factor into the host cytosol by forming a transmembrane channel. PA is the immunodominant antigen in available anthrax vaccines and a key therapeutic target for neutralizing antibodies. The protein contains four domains, each mediating specific steps in receptor binding, oligomerization, membrane insertion, and enzymatic factor translocation. Blocking PA function abrogates anthrax toxin activity and prevents infection.

Other names
Protective antigenPAAnthrax protective antigenBacillus anthracis protective antigenPA83 (full-length)PA63 (activated form)PA20 (cleaved fragment)
02

Mechanism of action

Neutralizing monoclonal antibodies: bind PA and block its interaction with host cell receptors or prevent oligomerization and pore formation, thus preventing translocation of lethal factor and edema factor Vaccine-induced antibodies: stimulate immune system to produce neutralizing antibodies that block PA binding and function

03

Biological functions

Host cell binding (mediates attachment of anthrax toxin to mammalian cells)Translocation of toxic enzymes (facilitates entry of lethal factor and edema factor into cytosol)Membrane pore formation (forms oligomeric β-barrel pores)
04

Disease associations

Infection (essential for the pathogenicity of Bacillus anthracis, causes anthrax)
05

Safety considerations

Rapid intoxication by processed toxin can limit window for therapeutic interventionRisk of hypersensitivity or allergic response to PA-based vaccines or antibodies
06

Interacting drugs

Raxibacumab (monoclonal antibody)

2 more in the full profile.

07

Biomarkers

Anti-PA antibody titers (used to assess vaccine efficacy and immune response)

Beyond the preview

Go deeper on Protective antigen protein (Bacillus anthracis) (PA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protective antigen protein (Bacillus anthracis) (PA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call